Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Decoy20,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
Details : Decoy20 is single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.
Product Name : Decoy20
Product Type : Microorganism
Upfront Cash : Undisclosed
July 26, 2021
Lead Product(s) : Decoy20,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement